Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Learning lessons from Pfizer's $800 million failure

The catastrophic failure of Pfizer's torcetrapib looked like it might doom an entire class of cholesterol modulators, but next month Merck will move its anacetrapib into one of the largest cardiovascular trials ever. Asher Mullard investigates how drug developers have reignited hope for the CETP inhibitors.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Get just this article for as long as you need it


Prices may be subject to local taxes which are calculated during checkout

Figure 1

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Learning lessons from Pfizer's $800 million failure. Nat Rev Drug Discov 10, 163–164 (2011).

Download citation

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research